Clinical Trials Logo

NSCLC clinical trials

View clinical trials related to NSCLC.

Filter by:

NCT ID: NCT03058094 Withdrawn - NSCLC Clinical Trials

A Study Comparing AC0010 and Chemotherapy in Patients With Advanced NSCLC Who Have Progressed Following Prior EGFR TKI

Start date: December 2018
Phase: Phase 3
Study type: Interventional

A Phase III, Open-Label, Randomized Multicenter Study to Compare AC0010 and Pemetrexed/Cisplatin in Patients With Advanced NSCLC Who Have Progressed Following Prior EGFR TKI.

NCT ID: NCT03030430 Completed - NSCLC Clinical Trials

Study of Bevacizumab(BAT1706) and Comparators in Healthy Subjects

Start date: March 15, 2016
Phase: Phase 1
Study type: Interventional

The purpose of this study is to establish PK similarity in the treatment of BAT1706 and comparators.

NCT ID: NCT02976116 Completed - NSCLC Clinical Trials

A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer

Start date: December 2016
Phase: Phase 2
Study type: Interventional

Fruquintinib in combination with Gefitinib as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harboring activating EGFR mutations : a single-arm, multicenter, phase II study

NCT ID: NCT02975609 Not yet recruiting - NSCLC Clinical Trials

Phase II Trial of SBRT Compared With Conventional Radiotherapy for Oligometastatic Non-Small Cell Lung Cancer

Start date: November 2016
Phase: Phase 2
Study type: Interventional

This protocol is a phase II randomized controlled trial (RCT) evaluating the efficacy of SBRT compared with conventional fractionated radiotherapy for oligometastatic Non-Small Cell Lung Cancer

NCT ID: NCT02973789 Active, not recruiting - NSCLC Clinical Trials

Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)

Start date: December 2016
Phase: Phase 3
Study type: Interventional

The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of TTFields, using the NovoTTF-200T device, concurrent with standard therapies for stage 4 NSCLC patients, following progression while on or after platinum based treatment. The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields (termed TTFields or TTF) to the region of the malignant tumor, by means of surface, insulated electrode arrays.

NCT ID: NCT02973763 Active, not recruiting - NSCLC Clinical Trials

Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Alflutinib in Advanced Non Small Cell Lung Cancer

Start date: December 30, 2016
Phase: Phase 1
Study type: Interventional

Alflutinib Mesylate Tablets is a Epidermal Growth Factor Receptor (EGFR) mutation selective Tyrosine Kinase Inhibitor which can efficient suppress the EGFR T790M drug-resistant mutation tumor cell in Xenograft mouse model. This study aims at local advanced or metastatic non-small cell lung cancer patients with T790M drug-resistant mutation.

NCT ID: NCT02954172 Completed - NSCLC Clinical Trials

Evaluate the Efficacy and Safety of IBI305 in Patients With Advanced or Recurrent Non-squamous NSCLC

Start date: November 28, 2016
Phase: Phase 3
Study type: Interventional

A randomized, double blind, multicenter phase3 study .

NCT ID: NCT02940990 Not yet recruiting - NSCLC Clinical Trials

SBRT in Multi-metastatic NSCLC Patients Which Are Pan-negative for Driver Mutations

Start date: November 2016
Phase: Phase 2
Study type: Interventional

This protocol is a phase II multi-center randomized controlled trial (RCT) evaluating the efficacy of SBRT in multi-metastatic NSCLC patients who are pan-negative for driver mutations.

NCT ID: NCT02905591 Recruiting - Clinical trials for Non-Small Cell Lung Cancer

A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC

XACT-LUNG
Start date: November 16, 2018
Phase: Phase 2
Study type: Interventional

This clinical trial evaluates adding high-dose ascorbate (vitamin C) to a standard therapy for non-small cell lung cancer. The standard therapy is radiation therapy combined with carboplatin and paclitaxel (types of chemotherapy). All subjects will receive high-dose ascorbate in addition to the standard therapy.

NCT ID: NCT02898116 Completed - Clinical trials for Non-small Cell Lung Cancer

Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer

Start date: May 10, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This was a Phase 1/2, open-label, multicenter, single-arm study of combination therapy with ensartinib, an anaplastic lymphoma kinase (ALK) inhibitor, and durvalumab, an anti-programmed cell death ligand 1 (PD-L1) antibody, in subjects with ALK-rearranged (ALK-positive) non-small cell lung cancer (NSCLC). Primary study objectives were to determine the recommended combination dose (RCD) and safety and tolerability of the combination. Further objectives were to evaluate the clinical efficacy and biologic activity of the combination.